AU2021226147A1 - Chelator compositions for radiometals and methods of using same - Google Patents

Chelator compositions for radiometals and methods of using same Download PDF

Info

Publication number
AU2021226147A1
AU2021226147A1 AU2021226147A AU2021226147A AU2021226147A1 AU 2021226147 A1 AU2021226147 A1 AU 2021226147A1 AU 2021226147 A AU2021226147 A AU 2021226147A AU 2021226147 A AU2021226147 A AU 2021226147A AU 2021226147 A1 AU2021226147 A1 AU 2021226147A1
Authority
AU
Australia
Prior art keywords
vivo
radioisotope
crown
peptide
targeting construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021226147A
Other languages
English (en)
Inventor
Francois Benard
Feng Gao
Paul Schaffer
Luke Wharton
Hua Yang
Zheliang YUAN
Chengcheng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
TRIUMF
Provincial Health Services Authority
Original Assignee
University of British Columbia
TRIUMF
Provincial Health Services Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, TRIUMF, Provincial Health Services Authority filed Critical University of British Columbia
Publication of AU2021226147A1 publication Critical patent/AU2021226147A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/086—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being alphaMSH, alpha melanocyte stimulating hormone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Peptides Or Proteins (AREA)
AU2021226147A 2020-02-25 2021-02-25 Chelator compositions for radiometals and methods of using same Pending AU2021226147A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062981113P 2020-02-25 2020-02-25
US62/981,113 2020-02-25
US202062993636P 2020-03-23 2020-03-23
US62/993,636 2020-03-23
PCT/CA2021/050226 WO2021168567A1 (en) 2020-02-25 2021-02-25 Chelator compositions for radiometals and methods of using same

Publications (1)

Publication Number Publication Date
AU2021226147A1 true AU2021226147A1 (en) 2022-09-22

Family

ID=77490568

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021226147A Pending AU2021226147A1 (en) 2020-02-25 2021-02-25 Chelator compositions for radiometals and methods of using same

Country Status (7)

Country Link
US (1) US20230270892A1 (enExample)
EP (1) EP4110768A4 (enExample)
JP (1) JP2023514784A (enExample)
AU (1) AU2021226147A1 (enExample)
CA (1) CA3172811A1 (enExample)
WO (1) WO2021168567A1 (enExample)
ZA (1) ZA202210224B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
CA3136979A1 (en) 2019-04-17 2020-10-22 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer
WO2022082312A1 (en) 2020-10-21 2022-04-28 Provincial Health Services Authority Novel cxcr4-targeting compounds
CN114807636B (zh) * 2021-12-31 2023-10-20 中国工程物理研究院核物理与化学研究所 一种无载体177Lu和161Tb的GMP生产方法
KR20240167790A (ko) * 2022-03-30 2024-11-28 니혼 메디피직스 가부시키가이샤 복합체의 제조 방법
CN119325393A (zh) * 2022-05-03 2025-01-17 北卡罗来纳大学教堂山分校 用于成像和治疗应用的靶向ntsr的试剂的开发
CN115286697B (zh) * 2022-09-29 2022-12-13 烟台蓝纳成生物技术有限公司 一种双重靶向化合物及其制备方法和应用
WO2024235273A1 (zh) * 2023-05-15 2024-11-21 成都社泰医疗科技有限公司 多靶向化合物及其应用
AU2024346916A1 (en) * 2023-09-22 2026-03-26 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
WO2025156030A1 (en) * 2024-01-25 2025-07-31 The University Of British Columbia 1,7,13-trioxa-4,10,16-triazacyclooctadecane chelator compositions for radiometals and methods of using same
WO2025171492A1 (en) * 2024-02-14 2025-08-21 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof
WO2025194281A1 (en) * 2024-03-22 2025-09-25 Triumf Inc. Chelator compositions for radiometals and methods of using same
CN118725025A (zh) * 2024-06-04 2024-10-01 厦门稀土材料研究所 用于177Lu标记的三齿类酰胺酸型双功能螯合剂及其制备方法和应用
WO2026000067A1 (en) * 2024-06-24 2026-01-02 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof
WO2026096892A1 (en) * 2024-11-01 2026-05-07 Ratio Therapeutics, Inc. Somatostatin binding compositions and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517814B2 (en) * 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
CN102212042A (zh) * 2011-04-18 2011-10-12 北京师范大学 一种四氮杂冠醚的合成方法
CN104151367B (zh) * 2014-08-06 2016-05-04 北京师范大学 一种稀土镧配合物及其合成方法
CN104151368B (zh) * 2014-08-06 2016-05-04 北京师范大学 一种稀土铕配合物及其合成方法
CA3100868A1 (en) * 2018-05-23 2019-11-28 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy

Also Published As

Publication number Publication date
US20230270892A1 (en) 2023-08-31
ZA202210224B (en) 2023-04-26
JP2023514784A (ja) 2023-04-10
CA3172811A1 (en) 2021-09-02
EP4110768A1 (en) 2023-01-04
WO2021168567A1 (en) 2021-09-02
EP4110768A4 (en) 2024-08-14

Similar Documents

Publication Publication Date Title
US20230270892A1 (en) Chelator compositions for radiometals and methods of using same
Boros et al. Chemical aspects of metal ion chelation in the synthesis and application antibody‐based radiotracers
Zeglis et al. A practical guide to the construction of radiometallated bioconjugates for positron emission tomography
CN113677400B (zh) 结合psma的双模式放射性示踪剂及治疗剂
Pandya et al. Preliminary therapy evaluation of 225Ac-DOTA-c (RGDyK) demonstrates that Cerenkov radiation derived from 225Ac daughter decay can be detected by optical imaging for in vivo tumor visualization
US12622984B2 (en) High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
US20210393809A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
JP2004529884A (ja) 金属放射性医薬のためのアスコルビン酸類似体
Luo et al. Development of [68Ga] Ga/[177Lu] Lu-DOTA-NI-FAPI-04 containing a nitroimidazole moiety as new FAPI radiotracers with improved tumor uptake and retention
US20240254085A1 (en) Chelators for radiometals and methods of making and using same
EP4291251B1 (en) Her2-binding polypeptide
Boros et al. Coordination chemistry and ligand design in the development of metal based radiopharmaceuticals
Lis et al. Development of [99mTc] TcO-ABX474: Design, Synthesis, and Biological Evaluation of PSMA-Binding Technetium-99m Radioligands for SPECT Imaging of Prostate Cancer
Bendre Fibroblast activation protein-targeted radioligands for cancer imaging and therapy
WO2025156030A1 (en) 1,7,13-trioxa-4,10,16-triazacyclooctadecane chelator compositions for radiometals and methods of using same
Fonge Jessica Pougoue Ketchemen1, Fabrice Ngoh Njotu1, 2, Hanan Babeker1, 2, Stephen Ahenkorah3, 4, Anjong Florence Tikum1, Emmanuel Nwangele1, 2, Nikita Henning1, Frederik Cleeren4, and Humphrey Fonge1, 5*. 1Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada
Li Metal chelating agents for medicinal radionuclides
Krenning et al. Panagiotis Kanellopoulos, Emmanouil Lymperis, Aikaterini Kaloudi, Marion de Jong 3
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
JP2026506464A (ja) 部位特異的ｕＰＡＲ標的化のための放射性核種標識ペプチドコンジュゲート
Yang et al. Novel Molecular Probes
WO2025194281A1 (en) Chelator compositions for radiometals and methods of using same
AU2021361746A1 (en) Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
Liu et al. Evaluation of a novel Tc-99m-labeled HYNIC-conjugated lactam bridge-cyclized alpha-MSH peptide for human melanoma imaging
KR20130128285A (ko) 아미노시클로헥산카르복실산-함유 시클로 ｒｇｄ 유도체, 그 제조방법 및 그것을 포함하는 ｐｅｔ 조영제